The income statement for the continuing operations has been made up by consolidating the income statements of the Allergy Sector and Chr. Hansen Holding, adjusted for intercompany transactions and net of the effects of the divestment of the Ingredients Sector.

The balance sheet as at August 31, 2005 of the continuing operations represents the sum of the balance sheets of the Allergy Sector and Chr. Hansen Holding and is identical to the assets, liabilities and equity stated in the consolidated balance sheet.

The notes to the financial statements contain supplementary information to help readers understand the split between the discontinued operations and the continuing operations.

Revenue from the continuing operations was DKK 1,217 million (1,054) corresponding to the Allergy Sector’s revenue. Cost of sales was attributable to the Allergy Sector and amounted to DKK 413 million (410) after elimination of intercompany transactions. Capacity costs relate to the Allergy Sector as well as Chr. Hansen Holding and are also stated net of intercompany transactions. The EBITA of the continuing business before the settlement of share options and amortization of goodwill was DKK 49 million (a loss of 55).